These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 2513160)
1. The effect of diltiazem on the disposition of encainide and its active metabolites. Kazierad DJ; Lalonde RL; Hoon TJ; Mirvis DM; Bottorff MB Clin Pharmacol Ther; 1989 Dec; 46(6):668-73. PubMed ID: 2513160 [TBL] [Abstract][Full Text] [Related]
2. Encainide disposition in patients with chronic cirrhosis. Bergstrand RH; Wang T; Roden DM; Avant GR; Sutton WW; Siddoway LA; Wolfenden H; Woosley RL; Wilkinson GR; Wood AJ Clin Pharmacol Ther; 1986 Aug; 40(2):148-54. PubMed ID: 3089668 [TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of encainide. Jaillon P Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833 [TBL] [Abstract][Full Text] [Related]
6. Encainide disposition in patients with renal failure. Bergstrand RH; Wang T; Roden DM; Stone WJ; Wolfenden HT; Woosley RL; Wilkinson GR; Wood AJ Clin Pharmacol Ther; 1986 Jul; 40(1):64-70. PubMed ID: 3087679 [TBL] [Abstract][Full Text] [Related]
7. Disposition kinetics of encainide and metabolites. Roden DM; Wood AJ; Wilkinson GR; Woosley RL Am J Cardiol; 1986 Aug; 58(5):4C-9C. PubMed ID: 3092618 [TBL] [Abstract][Full Text] [Related]
8. Influence of genetic polymorphism on the metabolism and disposition of encainide in man. Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808 [TBL] [Abstract][Full Text] [Related]
9. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. Carey EL; Duff HJ; Roden DM; Primm RK; Wilkinson GR; Wang T; Oates JA; Woosley RL J Clin Invest; 1984 Feb; 73(2):539-47. PubMed ID: 6421879 [TBL] [Abstract][Full Text] [Related]
10. The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine. Bottorff MB; Lalonde RL; Kazierad DJ; Hoon TJ; Tsiu SJ; Mirvis DM Pharmacotherapy; 1989; 9(5):315-21. PubMed ID: 2510135 [TBL] [Abstract][Full Text] [Related]
11. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. Funck-Brentano C; Turgeon J; Woosley RL; Roden DM J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225 [TBL] [Abstract][Full Text] [Related]
12. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. Turgeon J; Pavlou HN; Wong W; Funck-Brentano C; Roden DM J Pharmacol Exp Ther; 1990 Nov; 255(2):642-9. PubMed ID: 2123007 [TBL] [Abstract][Full Text] [Related]
13. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Turgeon J; Funck-Brentano C; Gray HT; Pavlou HN; Prakash C; Blair IA; Roden DM Clin Pharmacol Ther; 1991 May; 49(5):488-96. PubMed ID: 1903098 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of encainide in patients with cirrhosis. Wensing G; Mönig H; Ohnhaus EE; Hoensch HP Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559 [TBL] [Abstract][Full Text] [Related]
16. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Woosley RL; Roden DM; Dai GH; Wang T; Altenbern D; Oates J; Wilkinson GR Clin Pharmacol Ther; 1986 Mar; 39(3):282-7. PubMed ID: 3081292 [TBL] [Abstract][Full Text] [Related]
17. Drug interaction studies and encainide use in renal and hepatic impairment. Quart BD; Gallo DG; Sami MH; Wood AJ Am J Cardiol; 1986 Aug; 58(5):104C-113C. PubMed ID: 2875643 [TBL] [Abstract][Full Text] [Related]
18. Hemodialysis clearance of encainide and metabolites. Halvorsen MB; Whitmer JT; Halstenson CE Ther Drug Monit; 1991 Jul; 13(4):375-8. PubMed ID: 1780973 [TBL] [Abstract][Full Text] [Related]
19. Metabolite cumulation during long-term oral encainide administration. Kates RE; Harrison DC; Winkle RA Clin Pharmacol Ther; 1982 Apr; 31(4):427-32. PubMed ID: 6800679 [TBL] [Abstract][Full Text] [Related]
20. A high-performance liquid chromatographic method for the determination of encainide and its major metabolites in urine and serum using solid-phase extraction. Kazierad DJ; Hoon TJ; Bottorff MB Ther Drug Monit; 1989; 11(3):327-31. PubMed ID: 2499083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]